Abstract |
The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity. Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa.
|
Authors | Jacob A Lykke, Thor Grønlykke, Jens Langhoff-Roos |
Journal | Acta obstetricia et gynecologica Scandinavica
(Acta Obstet Gynecol Scand)
Vol. 87
Issue 11
Pg. 1248-51
( 2008)
ISSN: 1600-0412 [Electronic] United States |
PMID | 18850332
(Publication Type: Journal Article)
|
Chemical References |
- Factor Xa Inhibitors
- Fibrinolytic Agents
- Heparin, Low-Molecular-Weight
- Tinzaparin
|
Topics |
- Adult
- Dose-Response Relationship, Drug
- Factor Xa Inhibitors
- Female
- Fibrinolytic Agents
(therapeutic use)
- Gestational Age
- Heparin, Low-Molecular-Weight
(therapeutic use)
- Humans
- Parity
- Pregnancy
- Pregnancy Complications, Cardiovascular
(drug therapy)
- Pregnancy Outcome
- Retrospective Studies
- Risk Assessment
- Tinzaparin
- Treatment Outcome
- Venous Thrombosis
(drug therapy)
|